drugset / Trial / NCT06695741
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2027-02-01
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-lymphocyte globulin | Unknown | 25 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 20 mg/kg | — |
| Subject | RAFUTROMBOPAG | Other / unclassified | 15 mg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | — |
| Background | Cyclosporine | Peptide | 5 mg/kg | — |